TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8576674

Group type: EXPERIMENTAL
Intervention: Strengthened physician-nurse collaboration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multidisciplinary team approach
Number of subjects: 0
Study: 2016152

Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Cefotaxime
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Ceftazidime
Number of subjects: 223

Group type: COMPARATOR
Intervention: No antibiotic prophylaxis
Number of subjects: 223
Study: 7472106

Group type: EXPERIMENTAL
Intervention: Heparin-containing infusates
Number of subjects: 49

Group type: COMPARATOR
Intervention: Standard infusates (Control)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control group (Standard infusates)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Heparin group
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Heparinized fluids
Number of subjects: 49
Study: 4038553

Group type: EXPERIMENTAL
Intervention: Oral dexamethasone (2-week tapering dose from 0.15 mg/kg/d)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 28950422

Group type: EXPERIMENTAL
Intervention: Liraglutide 3.0 mg
Number of subjects: 5908

Group type: COMPARATOR
Intervention: Comparator group (placebo or orlistat)
Number of subjects: 5908
Study: 25851331

Group type: EXPERIMENTAL
Intervention: Case-based e-learning (14 short screencasts, each 5 minutes, plus a 60-minute on-site discussion)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Classroom-based presentations
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Objective structured clinical exam
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Test B (MC test directly after HT)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Test C (MC test 1 day after the course)
Number of subjects: 62
Study: 25332476

Group type: EXPERIMENTAL
Intervention: Unsaturated fatty acids (UNSAT) meal
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Saturated fatty acids (SFA) meal
Number of subjects: 21
Study: 22613271

Group type: EXPERIMENTAL
Intervention: Intramuscular cholecalciferol (600,000 IU)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Oral cholecalciferol (600,000 IU)
Number of subjects: 116
Study: 20411443

Group type: EXPERIMENTAL
Intervention: Internet self-management program
Number of subjects: 2603

Group type: EXPERIMENTAL
Intervention: Proactive volunteers vs. telephone respondents
Number of subjects: 2603
Study: 17506591

Group type: EXPERIMENTAL
Intervention: Imidapril (5 mg/day to 20 mg/day)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Candesartan cilexetil (4 mg/day to 16 mg/day)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Imidapril
Number of subjects: 112

Group type: COMPARATOR
Intervention: Candesartan cilexetil
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 112
Study: 15956037

Group type: EXPERIMENTAL
Intervention: 12 cycles of CMF chemotherapy
Number of subjects: 1241

Group type: COMPARATOR
Intervention: 6 cycles of CMF chemotherapy
Number of subjects: 1241

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 1241
Study: 12419084

Group type: COMPARATOR
Intervention: Conjugated equine estrogens (CEE) 0.625 mg/day and medroxyprogesterone acetate (MPA) 5 mg/day
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Tibolone 2.5 mg/day
Number of subjects: 50
Study: 10331686

Group type: EXPERIMENTAL
Intervention: Peak tibial lead levels
Number of subjects: 543

Group type: EXPERIMENTAL
Intervention: DMSA‐chelatable lead
Number of subjects: 543
Study: 7813349

Group type: EXPERIMENTAL
Intervention: Lateral internal anal sphincterotomy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Anal advancement flap
Number of subjects: 40
Study: 1958979

Group type: EXPERIMENTAL
Intervention: Nissen fundoplication
Number of subjects: 50

Group type: COMPARATOR
Intervention: Angelchik prosthesis
Number of subjects: 50
Study: 7051729

Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 60

Group type: COMPARATOR
Intervention: Thiopentone
Number of subjects: 60
Study: 31133052

Group type: EXPERIMENTAL
Intervention: Post-procedural oral hydration volume (quartiles)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous hydration (aggressive or routine)
Number of subjects: 0
Study: 30594256

Group type: EXPERIMENTAL
Intervention: Smart phone‐based event recorder (AliveCor Heart Monitor and AliveECG) alongside standard care
Number of subjects: 242

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 242
Study: 26341364

Group type: EXPERIMENTAL
Intervention: TURN score (Thrombolysis risk Using mRS and NIHSS)
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: TURN score
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: 24-hour brain swelling
Number of subjects: 303
Study: 25456808

Group type: EXPERIMENTAL
Intervention: Intervention group (IG; n = 428) received feedback about children's urine cotinine level (CUCL) and up to two counseling sessions.
Number of subjects: 852

Group type: COMPARATOR
Intervention: Control group (CG; n = 424) received a leaflet.
Number of subjects: 852

Group type: EXPERIMENTAL
Intervention: Intervention group (IG)
Number of subjects: 852
Study: 22057473

Group type: EXPERIMENTAL
Intervention: Group Genetic Counseling (GC)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Individual Genetic Counseling (GC)
Number of subjects: 65
Study: 20530651

Group type: EXPERIMENTAL
Intervention: Short-term intensive therapeutic exercise programme (n=22)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Home-based exercise advice (n=20)
Number of subjects: 42
Study: 18696023

Group type: EXPERIMENTAL
Intervention: Training intervention (40 sessions, 3 times per week) in NHF patients
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Training intervention in IHF patients
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (15 patients)
Number of subjects: 60
Study: 15649850

Group type: EXPERIMENTAL
Intervention: Inhaled salmeterol (50 microg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Oral slow-release theophylline (Theo-Dur, 600 mg tablets)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Combination of salmeterol and theophylline
Number of subjects: 10

Group type: COMPARATOR
Intervention: Theophylline (600 mg)
Number of subjects: 10
Study: 11960266

Group type: EXPERIMENTAL
Intervention: Blood stem cell (BSC) donation with G-CSF 10 microg/kg s.c., daily for 5 days before leukapheresis
Number of subjects: 61

Group type: COMPARATOR
Intervention: Bone marrow (BM) donation
Number of subjects: 61
Study: 10484534

Group type: EXPERIMENTAL
Intervention: Lp(a) plasma concentrations
Number of subjects: 826

Group type: EXPERIMENTAL
Intervention: Low molecular weight apo(a) phenotypes
Number of subjects: 826
Study: 8602746

Group type: EXPERIMENTAL
Intervention: Interferon beta‐1a (6.0 million units, 30 micrograms, administered by intramuscular injection weekly)
Number of subjects: 301

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Interferon beta‐1a
Number of subjects: 301
Study: 2011088

Group type: EXPERIMENTAL
Intervention: Surfactant treatment
Number of subjects: 33

Group type: COMPARATOR
Intervention: Conventional therapy with mechanical ventilation alone (Control)
Number of subjects: 33
Study: 7156001

Group type: EXPERIMENTAL
Intervention: Double blind ribosomal vaccine
Number of subjects: 61
Study: 30328708

Group type: EXPERIMENTAL
Intervention: Mechanical noise applied via piezoelectric actuators
Number of subjects: 40

Group type: COMPARATOR
Intervention: No mechanical noise (control)
Number of subjects: 40
Study: 29504585

Group type: EXPERIMENTAL
Intervention: High impact exercise training (6-month multidirectional hopping programme)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 50
Study: 26338433

Group type: EXPERIMENTAL
Intervention: High-intensity, variable stepping training (70%-80% heart rate reserve), 1-hour sessions, 10 weeks
Number of subjects: 32

Group type: COMPARATOR
Intervention: Conventional interventions determined by clinical physical therapists
Number of subjects: 32
Study: 25268853

Group type: EXPERIMENTAL
Intervention: Transdermal 17β estradiol (t‐E2) 50 μg/day plus micronized progesterone (m‐P) for 12 days
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Oral conjugated equine estrogen (o‐CEE) 0.45 mg/day plus micronized progesterone (m‐P) for the first 12 days of the month
Number of subjects: 116

Group type: COMPARATOR
Intervention: Placebo pills and patch
Number of subjects: 116
Study: 22811084

Group type: EXPERIMENTAL
Intervention: Silver catheters
Number of subjects: 325

Group type: COMPARATOR
Intervention: Plain catheters
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: EVD infection
Number of subjects: 325
Study: 20819468

Group type: EXPERIMENTAL
Intervention: Mometasone furoate (MF)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 17433901

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin
Number of subjects: 0

Group type: COMPARATOR
Intervention: No treatment or placebo
Number of subjects: 0
Study: 15513975

Group type: EXPERIMENTAL
Intervention: Acarbose 300 mg/day
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Metformin 1700 mg/day
Number of subjects: 30
Study: 12087449

Group type: EXPERIMENTAL
Intervention: Irinotecan plus 5-fluorouracil and folinic acid
Number of subjects: 0

Group type: COMPARATOR
Intervention: 5-fluorouracil and folinic acid
Number of subjects: 0
Study: 9869231

Group type: EXPERIMENTAL
Intervention: Normal hemoglobin levels (Hgb > or = 14.5 gm% for men, > or = 13 gm% for women)
Number of subjects: 451

Group type: COMPARATOR
Intervention: Anemic patients (Hgb < 14.5 gm% for men, < 13 gm% for women)
Number of subjects: 451
Study: 7808776

Group type: EXPERIMENTAL
Intervention: Chlorhexidine rinse
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Toothbrushing with conventional toothpaste
Number of subjects: 0
Study: 2698902

Group type: EXPERIMENTAL
Intervention: Daflon 500 mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 4833964

Group type: EXPERIMENTAL
Intervention: Naloxone (single dose)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Naloxone (repeated doses)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Naloxone (continuous infusions)
Number of subjects: 6
Study: 30139537

Group type: EXPERIMENTAL
Intervention: Medication Review (MR)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Patient selection by the number of prescribed drugs
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Perceived personal advantage of MR
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Initiation of MR
Number of subjects: 78
Study: 27182024

Group type: EXPERIMENTAL
Intervention: Self-directed feedback practice using smartphone videos
Number of subjects: 58
Study: 24325891

Group type: EXPERIMENTAL
Intervention: Driving Behavior Survey (DBS) scores
Number of subjects: 40
Study: 22830463

Group type: EXPERIMENTAL
Intervention: Sirolimus
Number of subjects: 120

Group type: COMPARATOR
Intervention: Calcineurin inhibitors
Number of subjects: 120
Study: 20830241

Group type: EXPERIMENTAL
Intervention: EGCG cream (2.5% w/w) applied twice daily for six weeks
Number of subjects: 4
Study: 17499035

Group type: EXPERIMENTAL
Intervention: Intracavity triamcinolone 80 mg (Group A, n=29)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Saline (Group B, n=23)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Intracavity triamcinolone 80 mg (Group A)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Saline (Group B)
Number of subjects: 49
Study: 16639473

Group type: EXPERIMENTAL
Intervention: Isometric endurance of the vastus lateralis muscle in CHF patients
Number of subjects: 25

Group type: COMPARATOR
Intervention: Isometric endurance of the vastus lateralis muscle in healthy subjects (HS)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Citrate synthase (CS) activity in CHF patients
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Hexokinase (HK) activity in CHF patients
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Phosphofructokinase (PFK) activity in CHF patients
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Correlation of T(F) with CS activity
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Correlation of T(F) with HADH activity
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Correlation of T(F) with PFK activity
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Correlation of T(F) with HK activity
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Correlation of T(F) with PFK/CS ratio
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Correlation of T(F) with HADH activity in CHF group
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Correlation of T(F) with PFK activity in CHF group
Number of subjects: 25
Study: 12798615

Group type: EXPERIMENTAL
Intervention: vax‐TyVi (Salmonella Typhi Vi polysaccharide vaccine)
Number of subjects: 0

Group type: COMPARATOR
Intervention: TYPHIM Vi (control vaccine)
Number of subjects: 0

Group type: COMPARATOR
Intervention: tetanus toxoid vaccine (control)
Number of subjects: 0
Study: 11028464

Group type: EXPERIMENTAL
Intervention: Mechanical valve
Number of subjects: 575

Group type: COMPARATOR
Intervention: Bioprosthetic valve
Number of subjects: 575

Group type: COMPARATOR
Intervention: Bioprosthetic AVR
Number of subjects: 575

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 575
Study: 8606270

Group type: EXPERIMENTAL
Intervention: Low dose dobutamine (5 to 10 microg/kg body weight per min)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: High dose dobutamine (20 to 40 microg/kg body weight per min)
Number of subjects: 49
Study: 8179456

Group type: EXPERIMENTAL
Intervention: Transdermal nicotine (14 mg/d, increased to 21 mg/d if smoking more than seven cigarettes after 1 week)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Transdermal placebo
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Transdermal nicotine
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Transdermal nicotine and placebo
Number of subjects: 156
Study: 2851195

Group type: EXPERIMENTAL
Intervention: Standard heparin, 5,000 I.U.
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Kabi 2165, 10,000 anti‐Xa U
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6

Group type: COMPARATOR
Intervention: Kabi 2165, 5,000 anti‐Xa U
Number of subjects: 6
Study: 30964340

Group type: EXPERIMENTAL
Intervention: Dark play
Number of subjects: 157

Group type: COMPARATOR
Intervention: Normal play
Number of subjects: 157
Study: 28548024

Group type: EXPERIMENTAL
Intervention: Omarigliptin 25 mg once-weekly
Number of subjects: 751

Group type: COMPARATOR
Intervention: Glimepiride up to 6 mg once daily
Number of subjects: 751
Study: 27345747

Group type: EXPERIMENTAL
Intervention: SMT+HEA
Number of subjects: 241

Group type: COMPARATOR
Intervention: HEA
Number of subjects: 241

Group type: COMPARATOR
Intervention: SRE+HEA
Number of subjects: 241
Study: 23340506

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 21103657

Group type: EXPERIMENTAL
Intervention: Solulin (0.6-30 mg single doses)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Solulin (1 and 10 mg multiple doses)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 19470722

Group type: EXPERIMENTAL
Intervention: ECGs with erroneous computer interpretation (citing acute ischemia)
Number of subjects: 105

Group type: COMPARATOR
Intervention: ECGs without erroneous computer interpretation
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Residents who read the ECG as diagnostic of ischemia with erroneous computer interpretation
Number of subjects: 105

Group type: COMPARATOR
Intervention: Residents who read the ECG as diagnostic of ischemia without erroneous computer interpretation
Number of subjects: 105
Study: 16881775

Group type: EXPERIMENTAL
Intervention: Multimodal cognitive-behavioral treatment package
Number of subjects: 64

Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 64
Study: 15621114

Group type: EXPERIMENTAL
Intervention: AUC(0-4) > or = 4000 ng . h/mL or C(2) > or = 1450 ng/mL (no induction therapy)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: C(2) of 1043 +/- 151 ng/mL or AUC(0-4) of 3146 +/- 262 ng . h/mL (with induction therapy)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Induction therapy with basiliximab or thymoglobulin
Number of subjects: 58
Study: 11212082

Group type: EXPERIMENTAL
Intervention: Nafarelin
Number of subjects: 1014

Group type: COMPARATOR
Intervention: Other GnRH agonists
Number of subjects: 1014
Study: 9289451

Group type: EXPERIMENTAL
Intervention: Amniotic fluid from women with pregnancy complicated by hypertension
Number of subjects: 62

Group type: COMPARATOR
Intervention: Amniotic fluid from healthy pregnant women (control group)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Fetal kidney maturation in pregnancy complicated by hypertension
Number of subjects: 62
Study: 2055157

Group type: EXPERIMENTAL
Intervention: Flupirtine maleate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lorazepam
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 6496647

Group type: EXPERIMENTAL
Intervention: Thick hydrogel contact lens wear on one eye
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (contralateral eye without lens)
Number of subjects: 8
Study: 30612559

Group type: COMPARATOR
Intervention: Erythromycin
Number of subjects: 2107

Group type: COMPARATOR
Intervention: Levofloxacin
Number of subjects: 2107

Group type: COMPARATOR
Intervention: Moxifloxacin
Number of subjects: 2107

Group type: COMPARATOR
Intervention: Macrolides (azithromycin, clarithromycin, erythromycin)
Number of subjects: 2107

Group type: COMPARATOR
Intervention: Fluoroquinolones (ciprofloxacin, levofloxacin, moxifloxacin)
Number of subjects: 2107
Study: 30127595

Group type: EXPERIMENTAL
Intervention: Candesartan 32 mg alone
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Amlodipine 10 mg alone
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Candesartan 32 mg and Amlodipine 10 mg co-administration
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 20
Study: 25308749

Group type: EXPERIMENTAL
Intervention: Lower medical mistrust
Number of subjects: 671

Group type: EXPERIMENTAL
Intervention: Greater perceived self-efficacy
Number of subjects: 671

Group type: EXPERIMENTAL
Intervention: Medical mistrust
Number of subjects: 671
Study: 23690319

Group type: EXPERIMENTAL
Intervention: Practice facilitation activities
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: 24-visit practice facilitation protocol
Number of subjects: 19
Study: 20832121

Group type: EXPERIMENTAL
Intervention: Deep anterior lamellar keratoplasty (DALK)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Penetrating keratoplasty (PK)
Number of subjects: 56
Study: 18369721

Group type: EXPERIMENTAL
Intervention: Two types of sex (vaginal plus oral or anal)
Number of subjects: 711

Group type: EXPERIMENTAL
Intervention: Three types of sex (vaginal, oral, and anal)
Number of subjects: 711

Group type: COMPARATOR
Intervention: Vaginal sex only
Number of subjects: 711

Group type: EXPERIMENTAL
Intervention: Having >/= 4 lifetime sex partners
Number of subjects: 711

Group type: EXPERIMENTAL
Intervention: Having a casual sex partner and having multiple sex partners in the last 60 days
Number of subjects: 711
Study: 17803435

Group type: EXPERIMENTAL
Intervention: Olopatadine 0.2%
Number of subjects: 126

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 126
Study: 15166554

Group type: EXPERIMENTAL
Intervention: Propofol and remifentanil combination
Number of subjects: 24
Study: 11271695

Group type: EXPERIMENTAL
Intervention: Telephone interview
Number of subjects: 409

Group type: COMPARATOR
Intervention: Face-to-face interview
Number of subjects: 409

Group type: COMPARATOR
Intervention: Telephone interviews in telephone households
Number of subjects: 409

Group type: COMPARATOR
Intervention: Face-to-face interviews in non-telephone households
Number of subjects: 409
Study: 9603075

Group type: EXPERIMENTAL
Intervention: Pneumococcal vaccine administered at 1 day post-splenectomy
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Pneumococcal vaccine administered at 7 days post-splenectomy
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Pneumococcal vaccine administered at 14 days post-splenectomy
Number of subjects: 59

Group type: COMPARATOR
Intervention: Normal adult control group (n = 12)
Number of subjects: 59
Study: 8554468

Group type: EXPERIMENTAL
Intervention: Peroneal stimulator (PS) during treatment period
Number of subjects: 17

Group type: COMPARATOR
Intervention: No intervention (control period)
Number of subjects: 17
Study: 2675496

Group type: EXPERIMENTAL
Intervention: Magnesium (Mg 5‐longoral, Artesan GmbH)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 819446

Group type: EXPERIMENTAL
Intervention: Disodium etidronate
Number of subjects: 4

Group type: COMPARATOR
Intervention: No drug (control)
Number of subjects: 4
Study: 30982447

Group type: EXPERIMENTAL
Intervention: Synbiotic supplementation (2.0 × 10^8 CFU probiotics and 394 mg fructooligosaccharide)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Synbiotic supplementation
Number of subjects: 57
Study: 28664036

Group type: EXPERIMENTAL
Intervention: Virtual brain biopsy using imaging metrics (white matter diffusivity indices, grey matter T1-signal intensity values, basal ganglia volumes)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 150
Study: 25361829

Group type: EXPERIMENTAL
Intervention: Pretransplant diabetes
Number of subjects: 628

Group type: EXPERIMENTAL
Intervention: NODAT (t)
Number of subjects: 628

Group type: EXPERIMENTAL
Intervention: Randomised trials (1 to 4)
Number of subjects: 628
Study: 23249928

Group type: EXPERIMENTAL
Intervention: Fibrinogen concentrate
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 21777032

Group type: EXPERIMENTAL
Intervention: Total intravenous anesthesia with propofol (group T)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Regional anesthesia (group R)
Number of subjects: 45

Group type: COMPARATOR
Intervention: General inhalational anesthesia with sevoflurane (group S)
Number of subjects: 45
Study: 19780729

Group type: EXPERIMENTAL
Intervention: EPI-NO training
Number of subjects: 276
Study: 16144748

Group type: EXPERIMENTAL
Intervention: 16 mg buprenorphine tablets (two 8 mg tablets)
Number of subjects: 24

Group type: COMPARATOR
Intervention: 8 mg buprenorphine solution (1 ml at 8 mg/ml)
Number of subjects: 24